Content Block Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas sed enim sem. Nulla dapibus, sapien sed gravida tempus, odio velit porta odio, at ullamcorper purus nunc et enim. Pellentesque magna elit, accumsan in interdum non, convallis eu nunc. Aenean non placerat lacus. In dignissim augue justo, id commodo ex semper in. Etiam placerat pellentesque diam sit amet interdum. Aliquam nec orci tristique, vehicula ante et, efficitur mi. Sed eu porta ligula. Mauris tincidunt eros quis pretium sodales.

Nam molestie purus non scelerisque facilisis. Quisque convallis ligula ut turpis consectetur, at maximus elit dapibus. Ut vestibulum congue sem malesuada fringilla. In rutrum eleifend augue eu porta. Ut commodo neque ut justo fermentum, quis varius ipsum malesuada. Sed non tortor finibus, porta est in, tempus ipsum. Cras orci massa, vehicula id bibendum quis, bibendum vitae risus.

Suspendisse potenti. Aenean mattis accumsan mi, et sodales lacus suscipit sed. Proin et euismod enim. Ut finibus rutrum orci, a suscipit libero bibendum vel. Donec sed diam turpis. Proin id sapien at orci pharetra eleifend. Integer faucibus leo nec finibus commodo. Fusce quis arcu ex. Donec quis velit dolor. Quisque suscipit turpis arcu, a pulvinar elit scelerisque nec. Cras a magna eget erat congue viverra ullamcorper non est. Morbi vulputate ultrices nibh, vel lacinia libero pretium sed. Aenean mattis, justo id tincidunt iaculis, lectus massa elementum orci, sit amet venenatis leo ligula pharetra ipsum. Pellentesque ornare urna purus, et blandit dolor tristique at. Cras fringilla molestie enim, eget commodo quam cursus ut. Integer ac lacinia lectus, eget congue lacus.

Maecenas vel massa posuere, facilisis neque at, interdum augue. Aliquam tincidunt varius odio, vitae dapibus turpis. Curabitur vestibulum, diam ut ultricies tincidunt, sem libero efficitur lorem, ac pulvinar est ipsum at enim. Proin molestie aliquam tincidunt. Nunc facilisis sem a euismod aliquam. Ut ac diam ac urna pulvinar pharetra. Cras ligula tellus, ullamcorper ac mi non, mattis interdum libero. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis pulvinar lectus a ipsum fermentum condimentum. Etiam ut commodo risus. Aliquam eleifend quam in lorem convallis interdum. Sed nunc sapien, convallis sit amet urna fringilla, venenatis elementum tortor. Ut imperdiet libero est, id rutrum diam dapibus ac. Ut imperdiet lacinia felis. Mauris vitae ante vestibulum, commodo odio in, efficitur ipsum.

Vaccines remain one of the most effective ways to prevent COVID-19 infections and serious disease. With vaccination rates around the globe still increasing, recent estimates suggest that the majority of adults could be vaccinated against COVID-19 by mid-2022.1 However, current vaccines may not optimally protect against new variants and protection from both natural and vaccine immunity may diminish over time.2

On February 23rd 2022, we announced that we intend to submit data from both our booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine. 

Our Adjuvanted Recombinant Protein-based Vaccine Candidate

The vaccine antigen is the spike protein that will stimulate the immune system to produce antibodies against the virus
 

Our Commitment to Fighting COVID-19

Throughout the ongoing pandemic, we have joined forces to fight COVID-19
 

Frequently Asked Questions (FAQ)

Recent COVID-19 Press Releases

More on Vaccines

R&D Pipeline

mRNA Technology: Vaccines and Beyond

Vaccines: Innovation for Disease Prevention and Control

References

  1. GAVI. Covax Global Supply Forecast. Available at: https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20Forecast.pdf. Last accessed October 2021.
  2. Nature. COVID vaccines protect against Delta, but their effectiveness wanes. 19 August 2021. Available at: https://www.nature.com/articles/d41586-021-02261-8. Last accessed October 2021

MAT-GLB-2101926 02/2022 v3.0